oncgnostics GmbH has already reached the funding limit of € 750,000 on the crowdfunding platform seedmatch 39 days before the end of the campaign. The first funding threshold of € 100,000 was exceeded just 2.5 hours after the start of the seedmatch campaign on 14 December 2017.
The company is a spin-off of the University Women’s Hospital in Jena and develops — on the basis of patented epigenetic markers — highly reliable molecular biological tests for early detection, therapy decisions and follow-up care in cancer diagnostics.
The capital raised by the crowdinvestors will be used to advance the positioning and marketing of the GynTect® product together with distribution partners in the European and North American markets. In addition, further studies are to be conducted in order to achieve broad reimbursement of GynTect® by health insurance companies.